Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C; BEYOND Study Group..

Mult Scler. 2012 Feb;18(2):181-95. doi: 10.1177/1352458511418629.

PMID:
21952094
2.

Determinants of interferon β efficacy in patients with multiple sclerosis.

Killestein J, Polman CH.

Nat Rev Neurol. 2011 Apr;7(4):221-8. doi: 10.1038/nrneurol.2011.22. Review.

PMID:
21364522
3.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
4.

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study..

Neurology. 2010 Jun 8;74(23):1877-85. doi: 10.1212/WNL.0b013e3181e240d0.

PMID:
20530324
5.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group., O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
6.

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.

Hesse D, Sellebjerg F, Sorensen PS.

Neurology. 2009 Aug 4;73(5):372-7. doi: 10.1212/WNL.0b013e3181b04c98.

PMID:
19652141
7.

Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?

Hemmer B, Berthele A.

Nat Clin Pract Neurol. 2009 Mar;5(3):126-7. doi: 10.1038/ncpneuro1042.

PMID:
19262585
8.

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.

Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J.

J Immunol Methods. 2008 Jul 31;336(2):113-8. doi: 10.1016/j.jim.2008.03.014.

PMID:
18511063
9.

Predictive markers for response to interferon therapy in patients with multiple sclerosis.

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A.

Neurology. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b.

PMID:
18272865
10.

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.

Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G.

Mult Scler. 2008 Mar;14(2):212-8.

PMID:
17986510
11.

Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.

Files JG, Hargrove D, Delute L, Cantillon M.

J Interferon Cytokine Res. 2007 Aug;27(8):637-42.

PMID:
17784815
12.

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.

Neurology. 2007 Mar 27;68(13):977-84. Erratum in: Neurology. 2007 Aug 14;69(7):712.

PMID:
17389300
13.

Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.

Massart C, Gibassier J, Oger J, Le Page E, Edan G.

Clin Chim Acta. 2007 Feb;377(1-2):185-91. Erratum in: Clin Chim Acta. 2007 May 1;380(1-2):255.

PMID:
17123498
14.
15.

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group..

Neurology. 2005 Jul 12;65(1):33-9.

PMID:
15888603
16.

Understanding interobserver agreement: the kappa statistic.

Viera AJ, Garrett JM.

Fam Med. 2005 May;37(5):360-3.

17.

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.

Deisenhammer F, Schellekens H, Bertolotto A.

J Neurol. 2004 Jun;251 Suppl 2:II31-9. Review.

PMID:
15264110
18.

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW; IFNB Multiple Sclerosis Study Group..

Mult Scler. 2004 Apr;10(2):126-38.

PMID:
15124756
19.

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.

Brain. 2004 Feb;127(Pt 2):259-68.

PMID:
14607790
20.

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years.

Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, Antonelli G.

J Neurol Sci. 2003 Nov 15;215(1-2):3-8.

PMID:
14568120
Items per page

Supplemental Content

Support Center